

January 6, 2010

AnGes MG, Inc.

AnGes MG and Avontec of Germany Terminate Their Cross License Agreement

AnGes MG, Inc. announces that both parties, Avontec GmbH of Germany and AnGes MG, have agreed to terminate their cross license agreement that consisted of license rights concerning STAT-1 decoy oligo in respiratory and dermal indications in Asia, and NF-kB decoy oligonucleotide in psoriasis indication in Europe.

AnGes MG is currently reviewing its development structure for NF-kB decoy oligonucleotide on a global scale, and intends to continue its development activities seeking a new partner.